biostudies-literatureUnknown6(6)Wu L<h4>Importance</h4>Preclinical and clinical studies have suggested the neuroprotective effect of Panax notoginseng saponins (Xuesaitong soft capsules). However, robust evidence in patients with ischemic stroke is lacking.<h4>Objective</h4>To assess the efficacy and safety of Xuesaitong soft capsules in patients with ischemic stroke.<h4>Design, setting, and participants</h4>This multicenter, double-blind, placebo-controlled randomized clinical trial was conducted at 67 tertiary health centers in China from July 1, 2018, to June 30, 2020. Included patients were aged 18 to 75 years with a diagnosis of ischemic stroke and a National Institutes of Health Stroke Scale score between 4 and 15.<h4>Interventions</h4>Eligible patients were randomly assigned within 14 days after symptom onset to receiJAMA network opene2317574https://www.ebi.ac.uk/biostudies/studies/S-EPMC10282883biostudies-literatureEfficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China: A Randomized Clinical Trial.PMC10282883Qu CLi HWu LWang ALi CZang YZhuang XZhang MSong HWang LLi YYao ZJi XXia LFang QNie ZGao YXiong CWang XZhang CZhang BfalseEfficacy and Safety of Panax notoginseng Saponins in the Treatment of Adults With Ischemic Stroke in China: A Randomized Clinical Trial.<h4>Importance</h4>Preclinical and clinical studies have suggested the neuroprotective effect of Panax notoginseng saponins (Xuesaitong soft capsules). However, robust evidence in patients with ischemic stroke is lacking.<h4>Objective</h4>To assess the efficacy and safety of Xuesaitong soft capsules in patients with ischemic stroke.<h4>Design, setting, and participants</h4>This multicenter, double-blind, placebo-controlled randomized clinical trial was conducted at 67 tertiary health centers in China from July 1, 2018, to June 30, 2020. Included patients were aged 18 to 75 years with a diagnosis of ischemic stroke and a National Institutes of Health Stroke Scale score between 4 and 15.<h4>Interventions</h4>Eligible patients were randomly assigned within 14 days after symptom onset to recei2023-01-01T00:00:00Z2023 Jun2025-04-05T14:47:06.625Z2025-04-05T14:47:06.625ZS-EPMC102828833733890710.1001/jamanetworkopen.2023.17574